37 completed. 37 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 37 |
| Phase 2 | 5 | Completed 5 |
Follow Psychomotor Disorders: new trials by email Literature Review of Psychomotor Disorders trials Research Report on Psychomotor Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) BXCL501, Matching Placebo - Agitation,Psychomotor, Bipolar I Disorder | Phase 3 | Completed | BioXcel Therapeutics Inc | 452 | 2022-11-21 | 2026-08-07 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 408 | 2022-09-06 | 2026-08-13 |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Completed | BioXcel Therapeutics Inc | 151 | 2022-04-27 | 2026-08-11 |
| A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation AXS-05 (dextromethorphan-bupropion), Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 456 | 2021-06-17 | 2025-12-08 |
| Assessing Clinical Outcomes in Alzheimer's Disease Agitation AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Completed | Axsome Therapeutics, Inc. | 178 | 2020-12-31 | 2023-11-29 |
| Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film - Agitation Associated With Bipolar Disorder, Agitation,Psychomotor | Phase 3 | Completed | BioXcel Therapeutics Inc | 380 | 2020-02-24 | 2026-08-11 |
| Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia Sublingual film containing dexmedetomidine (BXCL501), Placebo Film - Agitation, Schizophrenia | Phase 3 | Completed | BioXcel Therapeutics Inc | 380 | 2020-01-24 | 2026-08-11 |
| A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Brexpiprazole - Alzheimer's Disease | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 259 | 2018-10-11 | 2023-11-14 |
| A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type Brexpiprazole, Placebo - Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 345 | 2018-05-16 | 2023-09-18 |
| Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial) Dexmedetomidine, Placebo - Delirium, Agitation | Phase 3 | Completed | University Hospital, Clermont-Ferrand | 168 | 2017-12-21 | 2026-05-13 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Placebo, AVP-786 - Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 601 | 2017-10-13 | 2024-11-20 |
| Addressing Dementia Via Agitation-Centered Evaluation AXS-05, Bupropion, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 2 / Phase 3 | Completed | Axsome Therapeutics, Inc. | 366 | 2017-07-13 | 2023-09-13 |
| Study of Mirtazapine for Agitation in Dementia Mirtazapine, Placebo - Dementia | Phase 3 | Completed | University of Sussex | 207 | 2017-01-01 | 2021-04-19 |
| Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU BACLOFEN, PLACEBO - Alcoholism | Phase 3 | Completed | Nantes University Hospital | 314 | 2016-06-27 | 2026-09-14 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children Dexmedetomidine, saline - Agitation | Phase 2 / Phase 3 | Completed | Assiut University | 90 | 2016-05-01 | 2020-07-14 |
| Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type AVP-786, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 387 | 2015-07-23 | 2023-02-13 |
| Safety and Efficacy of Nabilone in Alzheimer's Disease Nabilone, Placebo - Alzheimer Disease, Agitation | Phase 2 / Phase 3 | Completed | Sunnybrook Health Sciences Centre | 38 | 2015-01-01 | 2020-06-25 |
| Akathisia in Post Operative Outpatients Surgery Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration - Akathisia | Phase 3 | Completed | University Hospital, Strasbourg, France | 300 | 2013-10-01 | 2026-03-16 |
| Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Brexpiprazole, OPC-34712 - Agitation Associated With, Alzheimer's Disease | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 270 | 2013-09-01 | 2020-11-20 |
Showing 20 of 37. Sign in to see all of them.
Psychomotor Agitation (37) · Alzheimer Disease (19) · Dementia (10) · Schizophrenia (6) · Psychotic Disorders (4) · Cognitive Dysfunction (3) · Bipolar Disorder (2) · Delirium (2) · Dementia, Vascular (2) · Mental Disorders (2) · Nervous System Diseases (2) · Pain (2) · Aggression (1) · Agnosia (1) · Alcohol Withdrawal Delirium (1)
Aberrant Motor Behavior in Dementia (37) · Behavior (37) · Dyskinesias (37) · Neurobehavioral Manifestations (37) · Neurologic Manifestations (37) · Pathological Conditions, Signs and Symptoms (37) · Signs and Symptoms (37) · Behavioral Symptoms (36) · Nervous System Diseases (35) · Mental Disorders (30) · Neurocognitive Disorders (23) · Brain Diseases (21) · Central Nervous System Diseases (21) · Neurodegenerative Diseases (19)
Dexmedetomidine (7) · Haloperidol (4) · brexpiprazole (4) · Citalopram (2) · Loxapine (2) · Sodium Chloride (2) · Valproic Acid (2) · Acetaminophen (1) · Baclofen (1) · Bupropion (1) · Clonidine (1) · Lorazepam (1) · Memantine (1) · Mirtazapine (1) · Morphine (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (6) · Axsome Therapeutics, Inc. (4) · BioXcel Therapeutics Inc (4) · Alexza Pharmaceuticals, Inc. (2) · Alzheimer's Disease Cooperative Study (ADCS) (1) · Assiut University (1) · Bruce Pollock (1) · Forest Laboratories (1) · Griffin Hospital (1) · JHSPH Center for Clinical Trials (1) · Nantes University Hospital (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute on Aging (NIA) (1) · National Taiwan University Hospital (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)
United States (25) · Canada (5) · France (5) · Puerto Rico (3) · United Kingdom (3) · Australia (2) · Bulgaria (2) · China (2) · Germany (2) · Poland (2) · Russia (2) · Spain (2) · Ukraine (2) · Brazil (1) · Croatia (1)
BioXcel MM (2) · BioXcel MM, MD (2) · Robert S Fishman, MD (2) · Alex SR Souza, PhD (1) · Anton Porsteinsson, MD (1) · Bettina S. Husebo, MD, PhD (1) · Bruce G. Pollock, M.D., Ph.D. (1) · Bruce Pollock, MD (1) · Clive Ballard, MD, PhD (1) · Constantine Lyketsos, MD, MHS (1) · Dag Aarsland, MD, Phd (1) · Daniel Weintraub, MD (1) · Davengere Devanand, MD (1) · David Shade, Esq (1) · Eva Kohegyi, MD (1)
PMID 40681915, PMID 41533472, PMID 41961243, PMID 39108660, PMID 41591746, PMID 29163985, PMID 31708380, PMID 36002761, PMID 40847656, PMID 41439450, PMID 41689409, PMID 42052145, PMID 42502037, PMID 11087767, PMID 11133600, PMID 11473855, PMID 16677266, PMID 17416907, PMID 21765198, PMID 21810649, PMID 23422376, PMID 23611363, PMID 24549548, PMID 24806873, PMID 24914549, PMID 25791540, PMID 27247487, PMID 27524403, PMID 27542731, PMID 29136228, PMID 29746373, PMID 29866205, PMID 30753761, PMID 31182351, PMID 31322567, PMID 31547752, PMID 31672419, PMID 33620407, PMID 33712253, PMID 33853394, PMID 34344312, PMID 34532852, PMID 34688369, PMID 35191924, PMID 36198061, PMID 37929672, PMID 37930669, PMID 39534972, PMID 39800465, PMID 41160116
2017 (2), 1RC2AG036535 (1), 2008 (1), R01AG031348 (1), R01MH059666 (1), R01NR015226 (1), U01AG010483 (1)